Patient experiences of narcolepsy and idiopathic hypersomnia in the Nordics: a patient journey map.

Autor: Vesinurm M; Nordic Healthcare Group Oy, Helsinki, Finland.; Department of Industrial Engineering and Management, Aalto University School of Science, Espoo, Finland., Dünweber C; Takeda AS, Vallensbæk Strand, Denmark., Rimestad J; Takeda AS, Asker, Norway., Landtblom AM; Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden.; Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden., Jennum PJ; Department of Clinical Neurophysiology, Rigshospitalet, Danish Center for Sleep Medicine, Copenhagen, Denmark.
Jazyk: angličtina
Zdroj: Journal of sleep research [J Sleep Res] 2024 Oct 26, pp. e14376. Date of Electronic Publication: 2024 Oct 26.
DOI: 10.1111/jsr.14376
Abstrakt: Central disorders of hypersomnolence (CDH) are chronic diseases that significantly impact the lives of affected individuals. We aimed to explore the perspectives of individuals with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH), and the challenges they encounter in their daily lives and within the healthcare systems in the Nordics. Interviews with patients (N = 41) and healthcare professionals (n = 14) and a patient survey (n = 70) were conducted in 2022 in Denmark, Sweden, Finland, and Norway to develop a patient journey map that visualises the patient with CDH journey and provides insights into the difficulties faced by these individuals. The patient journey mapping approach was chosen to focus on the processes and experiences of patients, highlighting the challenges they confront. Our findings revealed that the process of receiving a CDH diagnosis, as well as subsequent misdiagnoses and treatment, can be protracted and burdensome. CDH diagnoses remain poorly understood by neurologists, general practitioners, and the public, resulting in adverse consequences, with patients reporting a mean (standard deviation [SD]) time from symptom onset to diagnosis of 8.4 (5.11) years and a mean (SD) of 5.5 (4.17) productive hours lost/day. The available non-pharmaceutical support for patients with CDH, encompassing medical, psychological, educational, and professional assistance, was insufficient. The generalisability of the findings to one specific diagnosis is limited due to the collective analysis of the CDH. These findings are invaluable for identifying disruptions in the patient with CDH journeys and for designing improved pathways for those with NT1, NT2, and IH in the future.
(© 2024 Takeda Pharmaceuticals International AG. Journal of Sleep Research published by John Wiley & Sons Ltd on behalf of European Sleep Research Society.)
Databáze: MEDLINE
Externí odkaz: